Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-11 4:00 pm Purchase | 2025-12-08 | 13G | Crescent Biopharma, Inc. CBIO | ForGrowth III PA B.V. | 1,677,852 6.100% | 1,677,852 (New Position) | Filing History |
| 2025-12-08 4:30 pm Purchase | 2025-12-04 | 13D | Crescent Biopharma, Inc. CBIO | Fairmount Funds Management LLC | 5,643,482 18.530% | 2,519,262 (+80.64%) | Filing History |
| 2025-10-14 3:41 pm Purchase | 2025-10-07 | 13G | Crescent Biopharma, Inc. CBIO | 1Globe Capital LLC | 1,425,432 10.300% | 528,720 (+58.96%) | Filing History |
| 2025-10-09 4:15 pm Purchase | 2025-10-02 | 13G | Crescent Biopharma, Inc. CBIO | TANG CAPITAL MANAGEMENT, LLC | 700,000 5.040% | 700,000 (New Position) | Filing History |
| 2025-08-20 5:20 pm Purchase | 2025-08-13 | 13G | Crescent Biopharma, Inc. CBIO | 1Globe Capital LLC | 896,712 6.450% | 896,712 (New Position) | Filing History |
| 2025-08-14 4:01 pm Purchase | 2025-06-30 | 13G | Crescent Biopharma, Inc. CBIO | BIOTECHNOLOGY VALUE FUND L P | 1,387,863 9.990% | 1,387,863 (New Position) | Filing History |
| 2025-08-14 2:24 pm Purchase | 2025-06-30 | 13G | Crescent Biopharma, Inc. CBIO | Logos Global Management LP | 575,000 4.100% | 575,000 (New Position) | Filing History |
| 2025-07-08 09:07 am Purchase | 2025-06-30 | 13G | Crescent Biopharma, Inc. CBIO | FMR LLC | 1,414,190 10.200% | 1,414,190 (New Position) | Filing History |
| 2025-06-23 6:32 pm Purchase | 2025-06-13 | 13D | Crescent Biopharma, Inc. CBIO | Fairmount Funds Management LLC | 3,124,220 19.990% | 3,124,220 (New Position) | Filing History |
| 2025-06-23 4:30 pm Purchase | 2025-06-13 | 13G | Crescent Biopharma, Inc. CBIO | Venrock Healthcare Capital Partners III, L.P. | 1,391,196 9.900% | 1,391,196 (New Position) | Filing History |
| 2025-06-20 4:05 pm Purchase | 2025-06-20 | 13D | Crescent Biopharma, Inc. CBIO | Adage Capital Management, L.P. | 50,912 0.370% | 50,912 (New Position) | Filing History |
| 2025-02-14 6:38 pm Sale | 2024-12-31 | 13G | GlycoMimetics, Inc. GLYC | RA Capital Management, L.P. | 0 0.000% | -63,830 (Position Closed) | Filing History |
| 2024-11-27 2:22 pm Purchase | 2024-11-25 | 13G | GlycoMimetics, Inc. GLYC | Logos Global Management LP | 50,000 7.800% | 50,000 (New Position) | Filing History |
| 2024-11-12 4:30 pm Sale | 2024-09-30 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 19,651 3.000% | -33,234 (-62.84%) | Filing History |
| 2024-11-06 5:41 pm Purchase | 2024-10-30 | 13G | GlycoMimetics, Inc. GLYC | RA Capital Management, L.P. | 63,830 9.900% | 63,830 (New Position) | Filing History |
| 2024-11-04 4:26 pm Purchase | 2024-10-29 | 13D | GlycoMimetics, Inc. GLYC | Adage Capital Management, L.P. | 50,912 7.900% | 50,912 (New Position) | Filing History |
| 2024-11-04 2:01 pm Sale | 2024-10-30 | 13G | GlycoMimetics, Inc. GLYC | Weinstein Benjamin | 500 0.100% | -33,539 (-98.53%) | Filing History |
| 2024-08-15 5:01 pm Sale | 2024-08-13 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 52,885 8.200% | -33,006 (-38.43%) | Filing History |
| 2024-08-14 4:13 pm Purchase | 2024-08-09 | 13G | GlycoMimetics, Inc. GLYC | Weinstein Benjamin | 34,039 5.300% | 34,039 (New Position) | Filing History |
| 2024-07-29 7:24 pm Purchase | 2024-07-25 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 85,891 13.300% | 85,891 (New Position) | Filing History |